Ocumension Therapeutics (FRA:5DG) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5DG Ocumension Therapeutics FRA:5DG
65 GF Score
Price €0.53
GF Value €2.04
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ocumension Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:5DG
65GF Score
Ocumension Therapeutics FRA:5DG
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ocumension Therapeutics (FRA:5DG) Overvalued in 2026?

Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued. The current stock price of €0.53 is trading 74.3% below its estimated GF Value™ of €2.04. GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:5DG:

  • Short Ratio:
  • GF Value™: €2.04 vs. price of €0.53 (74.3% below fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the FRA:5DG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocumension Therapeutics Business Description

Other Exchanges OCUTF:USA01477:Hong Kong
Address No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
65GF Score

Get the complete analysis for FRA:5DG

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price
€2.04
GF Value